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Abstract
Epstein-Barr virus (EBV) is implicated in the pathogenesis of multiple human tumours of lymphoid and epithelial origin. The
virus infects and immortalizes B cells establishing a persistent latent infection characterized by varying patterns of EBV
latent gene expression (latency 0, I, II and III). The CDK1 activator, Response Gene to Complement-32 (RGC-32, C13ORF15), is
overexpressed in colon, breast and ovarian cancer tissues and we have detected selective high-level RGC-32 protein
expression in EBV-immortalized latency III cells. Significantly, we show that overexpression of RGC-32 in B cells is sufficient
to disrupt G2 cell-cycle arrest consistent with activation of CDK1, implicating RGC-32 in the EBV transformation process.
Surprisingly, RGC-32 mRNA is expressed at high levels in latency I Burkitt’s lymphoma (BL) cells and in some EBV-negative BL
cell-lines, although RGC-32 protein expression is not detectable. We show that RGC-32 mRNA expression is elevated in
latency I cells due to transcriptional activation by high levels of the differentially expressed RUNX1c transcription factor. We
found that proteosomal degradation or blocked cytoplasmic export of the RGC-32 message were not responsible for the
lack of RGC-32 protein expression in latency I cells. Significantly, analysis of the ribosomal association of the RGC-32 mRNA
in latency I and latency III cells revealed that RGC-32 transcripts were associated with multiple ribosomes in both cell-types
implicating post-initiation translational repression mechanisms in the block to RGC-32 protein production in latency I cells.
In summary, our results are the first to demonstrate RGC-32 protein upregulation in cells transformed by a human tumour
virus and to identify post-initiation translational mechanisms as an expression control point for this key cell-cycle regulator.
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Introduction
Epstein-Barr virus (EBV) is a human gamma herpes virus
carried by greater than 90% of the world’s population as a largely
asymptomatic persistent latent infection in B-lymphocytes. Despite
the fact that EBV-infected cells proliferate indefinitely [1], effective
immune control usually prevents tumour outgrowth in healthy
hosts. EBV has however been shown to contribute to the
development of numerous human cancers e.g. Burkitt’s lympho-
ma, undifferentiated nasopharyngeal carcinoma, Hodgkin’s dis-
ease and AIDS-associated and transplant-associated immunoblas-
tic lymphomas (reviewed in [2]). Immortalization of resting B cells
by EBV in vitro leads to the generation of latently infected
lymphoblastoid cell lines (LCLs) that express all EBV latent
proteins: Epstein-Barr nuclear antigens (EBNAs) 1, 2, 3A, 3B, 3C,
-LP and Latent membrane proteins (LMPs) 1, 2A and 2B, in
addition to non-coding RNA species. This ‘full’ pattern of latent
gene expression is termed latency III. More restricted patterns of
latent gene expression were first detected in tumour cells; EBV-
positive Burkitt’s lymphoma (BL) cells express only one latent
antigen, EBNA 1 (latency I), where the malignant cells of
Nasopharyngeal carcinomas and Hodgkin lymphomas express
the LMPs in addition to EBNA1 (Latency II). Since the latency III
pattern of gene expression is only associated with EBV positive
tumours arising in immunosuppressed post-transplant or AIDS
patients, it appeared that latent gene expression was downregu-
lated during tumourigenesis as part of an immune-evasion
strategy. However, latency I and II phenotypes were subsequently
detected in healthy EBV-infected individuals indicating that EBV
positive cells display different patterns of latent gene expression
during the establishment of a persistent infection, raising the
possibility that the latency type of tumour cells may simply reflect
that of the precursor cell [3-4]. Non-dividing EBV-positive cells
lacking any latent gene expression have also been detected in
infected hosts (latency 0), demonstrating that infected cells can
‘shut-off’ latent gene expression when in a resting state [3].
EBV has the capacity to disrupt the G1/S, G2/M and mitotic
cell-cycle checkpoints, thus promoting the proliferation of infected
cells to facilitate the establishment of a persistent viral infection in
the host. Studies examining the G1/S checkpoint in primary B
cells infected with EBV in vitro have demonstrated that treatment
with genotoxins that induce the formation of adducts and cross-
links results in normal stabilisation and activation of p53 but the
cyclin-dependent kinase inhibitor (CDKI) p21
WAF1/CIP1 fails to
accumulate. As a result CDK2 remains active and cells can
progress into S phase with damaged DNA [5-6]. Interestingly, the
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strand DNA breaks appears to differ and both p53 and
p21
WAF1/CIP1 responses are maintained, indicating that EBV
modulates the response to different types of damage in different
ways [5-7]. Studies into the effects of EBV on the G2/M
checkpoint have demonstrated that although EBV-negative
Burkitt’s lymphoma cells treated with genotoxins arrest in G2/
M, EBV-infected derivatives of these cells continue to progress
through G2/M and are protected from apoptosis [8]. EBV-
positive cells are also able overcome G2 arrest induced by a
histone deacetylase inhibitor [9]. EBV infection of BL lines
additionally promotes survival following induction of the mitotic
spindle checkpoint by microtubule destabilising drugs through
both checkpoint disruption and reduced cell death mediated by
downregulation of the proapoptotic protein, Bim [10].
The essential latency III protein, EBNA 3C, has emerged as a
key player in EBV-mediated cell-cycle disruption; when expressed
alone in various cell-types EBNA 3C has the capacity to disrupt
the G1/S, G2/M and mitotic checkpoints [9,11–12]. Moreover,
EBNA 3C inactivation halts the growth of EBV-infected cells as a
result of transcriptional derepression of the CDKI p16
INK4a [13–
14]. Interestingly, cooperation between EBNA 3C and another
member of the EBNA 3 family, EBNA 3A has been shown to be
required for both repression of Bim and repression of p16
INK4a
through an epigenetic mechanism involving increased trimethyla-
tion of Histone H3 on lysine 27 at the gene loci [15–16]. There
have also been reports describing interactions between EBNA 3C
and multiple cell-cycle regulatory proteins including cyclin A,
cyclin D1, SCFSkp2, Rb, c-Myc, chk2, p53, Mdm2 and the p53
regulatory proteins ING4 and 5 [17–26].
Response Gene to Complement 32 (RGC-32, C13ORF15) was
identified in rat oligodendrocytes as a novel gene induced in
response to sub-lytic complement activation of the cell cycle [27].
Cloning of human RGC-32 cDNA from a foetal brain library
identified a cDNA encoding a protein of 117 amino acids with no
significant primary sequence homology to other human proteins
(AF036549) [28]. RGC-32 was shown to be expressed at the RNA
and protein level in a range of human tissues including brain, heart
and liver [28]. Consistent with a role in cell-cycle progression,
expression of RGC-32 in smooth muscle cells following G1 arrest
promotes S- and M-phase entry and RGC-32 has been shown to
bind and activate the key mitotic kinase, CDK1, in a manner
dependent on threonine 91 phosphorylation of RGC-32 by CDK1
[27–28]. Moreover, knock-down of RGC-32 prevents complement
and growth factor-induced cell-cycle entry and CDK1 activation
in aortic endothelial cells [29]. RGC-32 translocates from the
cytoplasm to the nucleus during cell-cycle activation or the onset of
mitosis and associates with centrosomes [28,30]. Interestingly,
RGC-32 has been shown to be overexpressed at the RNA and/or
protein level in multiple human tumours including those of the
colon, prostate, bladder, breast, lung and ovaries [31–33]. High-
level RGC-32 expression appears to correlate with late stage
disease, since increased RGC-32 RNA and protein levels are
detected in advanced stages of colon carcinoma, compared to
precancerous or early stage colon cancer tissues [34].
Although much evidence points to a role for RGC-32 in the
promotion of cell proliferation, some studies have implicated
RGC-32 as a tumour suppressor. The RGC-32 gene was found to
be frequently inactivated in glioma cell-lines, with RGC-32
expression levels correlating with the p53 status of the cell-lines
[30]. Further analysis revealed RGC-32 as a transcriptional target
of p53 [30]. The same study demonstrated that overexpression of
RGC-32 delayed progress through mitosis and suppressed the
growth of glioma cells, indicative of a negative effect on cell
growth. Microarray profiling of multiple myeloma plasma cells
and drug resistant glioblastomas has also detected underexpression
of RGC-32 mRNA [35–36] implicating downregulation of RGC-
32 in tumour development/progression. Recently, methylation of
the RGC-32 promoter region was associated with RGC-32
downregulation in non small cell lung cancers [37]. Since a
number of regulatory pathways have been reported to control
RGC-32 expression in a variety of cellular systems including TGF-
b signalling in neural crest cells and the MAPK pathway in aortic
and umbilical vein endothelial cells, it is likely that multiple
mechanisms may act to fine-tune RGC-32 expression in a cell-
type-specific manner (reviewed in [38]). Accumulating evidence
indicates that perturbation of these control mechanisms may play
a key role in the development of a diverse range of human cancers.
We have detected high-level RGC-32 protein expression in
Epstein-Barr virus-infected B-cells and provide the first demon-
stration that RGC-32 overexpression disrupts G2/M checkpoint
regulation, implicating RGC-32 in the EBV transformation
mechanism. We have identified key new control mechanisms for
the regulation of RGC-32 expression in EBV-infected human B-
cells. We show that RGC-32 mRNA expression is controlled by
the RUNX1c transcription factor leading to high level RGC-32
mRNA expression in cells displaying the restricted latency I form
of EBV gene expression. However, our data indicate that a post-
initiation translational block prevents RGC-32 protein expression
in EBV negative and latency I cells.
Results
RGC-32 protein is differentially upregulated in EBV-
positive cell-lines
Examination of RGC-32 expression in a panel of EBV-negative
and positive cell-lines revealed that RGC-32 protein was highly
expressed in EBV-infected lymphoblastoid cell-lines that express
the ‘full’ panel of latent gene expression, termed latency III
(Figure 1A). We also detected RGC-32 protein expression in a
latency III Burkitt’s lymphoma (BL) cell-line clone (Mutu III) that
had drifted in culture from an original BL line (Mutu I) displaying
the characteristic more restricted form of EBV gene expression,
latency I (EBNA 1 only) [39] (Figure 1A). In contrast, we were
unable to detect RGC-32 protein expression in all EBV negative
and EBV-positive latency I B-cell lines examined (Figure 1A and
data not shown). Moreover, RGC-32 protein expression was
induced on infection of two EBV negative BL cell-lines, BL2 and
BL31 with a recombinant EBV bacmid [15] (Figure 1B). Since
upregulation of RGC-32 expression has been linked to numerous
cancers [31–34], potentially through the role of RGC-32 as an
activator of the mitotic CDK1/cyclin B1 complex [27–28], these
results may implicate RGC-32 upregulation in EBV-mediated
tumourigenesis. To determine whether levels of RGC-32 fluctu-
ated during the cell cycle, we examined RGC-32 protein
expression in cell-cycle fractions obtained by centrifugal elutriation
from Mutu III cells (Figure 1C). Our results demonstrated that
total RGC-32 protein levels do not vary significantly during the
cell-cycle, indicating that any cell-cycle specific effects of RGC-32
are likely to be mediated through control of RGC-32 activity or
cell-cycle specific expression of RGC-32 targets.
Stable overexpression of RGC-32 alone is sufficient to
disrupt the G2/M checkpoint
To confirm the effects of RGC-32 on CDK1 activity we carried
out Histone H1 kinase assays using purified recombinant His-
tagged RGC-32 and observed a dose-dependent increase in
CDK1 activity in the presence of RGC-32 (Figure 2A). In replicate
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enhanced by an average of 11.6-fold (Figure 2B).
CDK1 is held in an inactive tyrosine 15 and threonine 14
phosphorylated form during interphase and is activated through
dephosphorylation by the cdc25 phosphatase at the end of G2,
allowing entry into mitosis. When the G2/M checkpoint is
triggered on exposure to DNA damaging agents, CDK1 activation
is prevented through the phosphorylation, sequestration and
degradation of cdc25, resulting in G2 arrest. Since we had
confirmed that RGC-32 could function as an activator of CDK1
(Figure 2A and B), we next examined whether overexpression of
RGC-32 alone was sufficient to disrupt the G2/M checkpoint in
B-cell lines. We created isogenic EBV negative B cell-lines (DG75
and BJAB) stably expressing Flag-tagged RGC-32 (FRT/RGC-32)
using the Flp-in system (Invitrogen). Control cell-lines and FRT/
RGC-32 cell-lines were then treated with the topoisomerase II
inhibitor, etoposide, to introduce DNA double strand breaks and
trigger the G2/M checkpoint. Our results demonstrated that in
contrast to DG75 FRT control cells that accumulated in G2/M
following etoposide treatment, DG75 FRT/RGC-32 cells dis-
played a higher proportion of cells in G0/G1 and reduced levels of
cells in G2/M indicating transit of a significant proportion of cells
through the checkpoint (Figure 2D). We observed a 2.6 and 3.2-
fold increase in the proportion of cells in G0/G1 in DG75 FRT/
RGC-32 cells compared to control cells following treatment for
24 hrs with 400 nM and 800 nM etoposide, respectively. RGC-32
expressing DG75 cells also displayed 60% and 52% decreases in
the G2/M population at these concentrations of etoposide,
compared to control cells. BJAB cells appeared to tolerate the
FRT expression system less well than DG75 cells, with increased
sub 2n populations in both control FRT cells and FRT/RGC-32
cells (Figure 2E). These cell-lines also displayed more sensitivity to
etoposide treatment and phenotypes were most evident when cells
were treated with lower etoposide concentrations for a longer time
(48 hrs). Nonetheless, clear differences were observed in the cell-
cycle distribution of BJAB FRT/RGC-32 cells compared to
control FRT cells in response to etoposide, with increased
numbers of cells in G0/G1 indicating increased passage of cells
through the G2/M checkpoint (Figure 2E). Interestingly, in the
BJAB FRT background, checkpoint disruption was represented by
a phenotype of a decreased S-phase population and an increased
G0/G1 population, with only a slight decrease in the G2/M
population. This observation is likely to result from the fact that
control BJAB/FRT cells appear to be arrested in both S and G2
phases, but in BJAB/RGC-32 cells both S phase and G2 cells
transit through the G2/M checkpoint and either die or re-enter
G1. Consistent with checkpoint transit, an increase in the G0/G1
population was observed in multiple etoposide experiments carried
out in BJAB/RGC-32 cells (Figure 2F). In both DG75 and BJAB
cell backgrounds, transit through the G2/M checkpoint in
etoposide-treated RGC-32 expressing cells also led to increases
in the sub 2n population indicative of the apoptotic death of some
cells unable to repair damaged DNA (Figure 2 C and D). In
summary, our results provide the first evidence that overexpression
of RGC-32 in two different B-cell backgrounds can disrupt the
G2/M checkpoint and suggest that upregulation of RGC-32 could
play a role in EBV-mediated cell-cycle deregulation in B-cells.
RGC-32 mRNA expression is highest in EBV positive
latency I cells
In follow-up experiments investigating the expression of RGC-
32 mRNA in a panel of EBV negative and positive B-cell lines, we
observed that RGC-32 mRNA expression was significantly higher
in latency I BL lines, and in some EBV-negative cell-lines,
compared to latency III cell-lines (Figure 3B). This was surprising
given that no RGC-32 protein expression is detectable in latency I
and EBV-negative cell-lines (Figure 1).
Two transcript variants of human RGC-32 have been
documented (Figure 3A). The shorter form, previously detected
in many cell types, lacks the end of exon 1 and the start of exon 2
[28](Figure 1). Database entries also document a longer form of
RGC-32, generated from alternative splice sites at the end of exon
1 and the start of exon 2, that encodes a protein with an additional
20 amino acids close to the N terminus (e.g. NM_014059).
Although the Q-PCR primers we used to detect RGC-32 mRNA
were within an exon region common to both transcript variants
(exon 3), we carried out further analysis to rule out the possibly
that these primers were failing to detect a novel alternatively
spliced RGC-32 transcript in latency III cells that lacks exon 3.
Conventional non-quantitative PCR across exons 2 to 4 produced
a single product in EBV-negative and EBV-positive latency I and
III cells that was consistent with the size expected if exon 3 were
present (248 bp) (Figure 3C). No shorter products indicating the
absence of exon 3 (140 bp) were detected (Figure 3C). Further Q-
PCR analysis using primers across exons 2 to 3 (Figure 3D) and
exons 4-5 (Figure 3E) also confirmed our original observations that
latency I cells express high levels of RGC-32 mRNA compared to
latency III cells. By way of final confirmation of this unexpected
mRNA expression profile, we also investigated the possibility that
our RGC-32-specific primers were detecting an additional
previously undocumented gene transcript in latency I cells that
spans the RGC-32 gene locus and utilizes common exons.
Northern blotting analysis using a probe generated from the
entire RGC-32 cDNA sequence verified that the only transcript
detectable in latency I cells had an approximate size of 900 nts,
consistent with the expression of the short-form of RGC-32. In line
with the lower sensitivity of Northern blotting vs Q-PCR, RGC-32
Figure 1. RGC-32 protein is selectively expressed in EBV
infected latency III cells. (A) Western blot analysis of RGC-32 protein
expression in a panel of EBV negative and positive B-cell-lines. Blots
were stripped and re-probed with anti-actin antibodies as a loading
control (B) Western blot analysis of RGC-32 protein expression in two
EBV negative BL cell-lines (BL2 and BL31) infected with recombinant
wild-type EBV bacmids [15]. (C) Western blot analysis of RGC-32 protein
expression in Mutu III cell-cycle fractions obtained by centrifugal
elutriation. Blots were probed for CDK1 and cyclin B1 as controls for
cell-cycle phases. Cell-cycle phases were confirmed by Flow cytometry
(Figure S1).
doi:10.1371/journal.pone.0028638.g001
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III latency III cells and were not detectable in LCLs.
Thus, using multiple approaches, we have demonstrated that
RGC-32 mRNA is expressed at high levels in EBV positive latency
I cells and some EBV negative cell lines despite a lack of RGC-32
protein expression, implicating post-transcriptional mechanisms in
the control of RGC-32 gene expression. It is clear however, that
the seemingly low levels of RGC-32 message expressed in latency
Figure 2. RGC-32 activates CDK1 and disrupts the G2/M checkpoint in B-cell lines. (A) Histone H1 kinase assay carried out using
recombinant CDK1/Cyclin B1 in the absence or presence of purified recombinant His-RGC-32. (B) Quantification of [
32P]-Histone H1 signals. Results
show mean fold increases in CDK1 activity in the presence of RGC-32 +/- standard deviation from 3 independent experiments. (C) Representative cell
cycle profile analysis of DG75 FRT control cells and DG75 FRT/FLAG-RGC-32 cells treated for 24 hours with etoposide. Control cells (0) were harvested
prior to etoposide treatment. (D) Representative cell cycle profile analysis of BJAB FRT control cells and BJAB FRT/FLAG-RGC-32 cells treated for 48
hours with etoposide. (E) Graph showing the percentage change in the G0/G1 population in BJAB FRT/FLAG-RGC-32 cells compared to control BJAB
FRT cells, prior to (0), or following etoposide treatment for 48 hours. Results represent the mean +/2 standard deviation of 3 independent
experiments.
doi:10.1371/journal.pone.0028638.g002
Figure 3. RGC-32 mRNA expression is differentially regulated in different types of EBV latency. (A) Diagram showing RGC-32 transcript
variants. Black boxes represent exons and dotted lines show the parts of exons 1 and 2 that are not included in the shorter RGC-32 transcript
(AF036549) that encodes a protein of 117 amino acids [28]. The longer RGC-32 (C13ORF15) transcript (NM_014059) is predicted to encode a protein
of 137 amino acids. (B) Q-PCR analysis using primers in exon 3. Transcript quantities were normalized to those of GAPDH and then expressed relative
to the signal obtained in DG75 cells. Results show the mean of 3 independent experiments +/2 standard deviation. (C) Non-quantitative PCR analysis
of cDNA samples using primers that amplify across exon 2 to exon 4. pFLAG-RGC-32 was used as a positive control (con). Q-PCR analysis using
primers that amplify across exons 2 and 3 (D) or exons 4 and 5 (E). Transcript quantities were normalized to GAPDH and results show the mean of 3
independent experiments +/2 standard deviation. (F) Northern blot analysis of RGC-32 transcripts. Blots were probed with a [
32P]-labelled probe
generated from the entire RGC-32 cDNA and then stripped and re-probed for GAPDH.
doi:10.1371/journal.pone.0028638.g003
Upregulation of RGC-32 in EBV-Infected Cells
PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e28638III cells are sufficient to support robust RGC-32 protein
expression in these cells (Figure 1).
RGC-32 mRNA expression in human B-cells is controlled
by RUNX1c
The differential RGC-32 mRNA expression we detected in
EBV positive cells resembles that previously documented for the
B-cell isoform of the RUNX1 transcription factor, RUNX1c [40-
41]. Latency-type dependent expression of RUNX1c results from
upregulation of the related RUNX3 transcription factor by EBNA
2 in latency III cells [40]. This leads to downregulation of RUNX1
expression, since RUNX3 directly represses RUNX1c transcrip-
tion by binding to RUNX sites close to the RUNX1 P1 promoter
[41]. RUNX1c expression is therefore high in latency I and low in
latency III cells. Consistent with the possibility that RUNX1 may
regulate RGC-32 transcription in human B-cells, previous reports
demonstrated that knockdown of rat RUNX1 resulted in reduced
RGC-32 mRNA expression in rat periovulatory cells. RUNX
binding sites in the rat RGC-32 promoter were subsequently
identified [42–43]. Further studies also identified mouse RGC-32
as a direct target of the RUNX 1, 2 and 3 transcription factors
when these proteins were overexpressed in fibroblasts [44].
Real-time PCR analysis of RUNX1c transcript levels and
Western blot analysis of RUNX1 protein expression in a panel of
EBV-negative and EBV-positive cell-lines confirmed previous
reports that high RUNX1 expression correlated with a EBV
latency I gene expression pattern [40-41]. RGC-32 mRNA
expression showed a correlation with RUNX1c expression; with
the highest levels detectable in latency I cell lines and some EBV
negative cell lines (compare Figure 4A and B with Figure 3B). We
next tested whether RUNX1c was able to activate transcription of
the human RGC-32 promoter in transient assays using an RGC-
32 promoter-reporter construct. We detected a statistically
significant greater than 2-fold activation of the RGC-32 promoter
by RUNX1c confirming the human RGC-32 promoter as a
RUNX1 target (Figure 4C). Consistent with these observations, we
found 6 potential RUNX sites in the region of the RGC-32
promoter present in the reporter construct. Further experiments
demonstrated that RUNX1c was able to upregulate endogenous
RGC-32 transcription. Expression of RUNX1c in an LCL with
characteristically low endogenous levels of RUNX1c, followed by
short-term drug selection of transfected cells, led to a statistically
significant 1.75-fold increase in endogenous RGC-32 mRNA
expression 6 days post-transfection (Figure 4D).
Proteasomal degradation or blocked message export do
not prevent RGC-32 protein expression in latency I cells
To investigate the lack of detectable RGC-32 protein expression
in latency I cells further, we examined the possibility that RGC-32
was translated but then rapidly degraded by the proteasome. The
Figure 4. RGC-32 is transcriptionally regulated by RUNX1c in B-cells. (A) Q-PCR analysis of RUNX1c mRNA levels. Transcript quantities were
normalized to those of GAPDH and then expressed relative to the signal obtained in DG75 cells. Results show the mean of 3 independent
experiments +/2 standard deviation. (B) Western blot analysis of RUNX1c protein expression in a panel of EBV negative and positive B-cell-lines. Actin
levels serve as a loading control. (C) Transient reporter assays in DG75 cells transfected with 4 mg of the RGC-32 promoter-reporter construct (pRGC-
32pluc), 2 mg pRL-CMV as a transfection control and increasing amounts (2.5, 5 and 10 mg) of a RUNX1c-expressing plasmid (pBK-CMV-RUNX1c).
Firefly luciferase signals were normalized to Renilla luciferase signals. Results show the mean of 3 independent experiments +/2 standard deviation.
RGC-32 promoter activation is expressed relative to the RUNX1-negative control. ** P value ,0.01 (0.004), * p value ,0.05 (0.036). (D) IB4 cells were
transfected with pCEP4 or pCEP4-RUNX1c plasmids and transfected cells selected in Hygromycin B. 6 days post-transfection samples were analysed
for RUNX1c protein expression by western blotting using actin as a loading control and endogenous RGC-32 mRNA expression using Q-PCR. Results
show the mean of 2 independent experiments 2/+ standard deviation. * P value ,0.05 (0.012).
doi:10.1371/journal.pone.0028638.g004
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treated with the proteasome inhibitor MG132 in parallel with the
IB4LCL(latency III).Treatment with 50or100 mM MG132forup
to 6 hrs did not result in the appearance of detectable RGC-32
protein in Mutu I cells (Figure 5A). Parallel treatment of IB4 cells
which express functional p53, showed that MG132 inhibition was
effective; p53 protein levels increased after MG132 treatment
(Figure 5A). MG132 treatment of Mutu III cells appeared to result
in some increase in RGC-32 protein levels, although levels of RGC-
32 in IB4 cells appeared unaffected. It is therefore possible that the
proteasome may play a role in regulating RGC-32 protein
expression in some latency III cell backgrounds. We next
investigated the possibility that RGC-32 protein was not translated
in latency I cells due to a block in the export of RGC-32 message to
the cytoplasm. Cytoplasmic and nuclear fractions were prepared
from Mutu I and Mutu III cells and protein and RNA extracted in a
parallel. Western blotting for a nuclear (Spt16) and cytoplasmic
marker (actin) confirmed the integrity of the fractions (Figure 5B).
The cytoplasmic and nuclear distribution of RGC-32 mRNA was
then determined by Q-PCR (Figure 5C) and compared to that of a
control message (GAPDH) that is highly expressed and efficiently
exported (Figure 5D). Our results demonstrated that although the
proportion of RGC-32 mRNA present in the cytoplasm was lower
than that of GAPDH, greater than 50% of the RGC-32 message
expressed in latency I cells was detectable in the cytoplasm
(Figure 5D) indicating that sufficient RGC-32 mRNA is available
in the cytoplasm for translation. These results therefore exclude
proteasomal degradation and blocked cytoplasmic export as
mechanisms preventing RGC-32 protein detection in latency I cells.
RGC-32 translation is blocked at a post-initiation stage in
latency I cells
Since our results thus far pointed to a block to RGC-32
translation in EBV-negative and EBV-positive latency I cells, we
investigated the possibility that translational repression may result
in stabilization of RGC-32 mRNA thus contributing to the high
levels of message in these cells. We therefore monitored the rate of
degradation of RGC-32 mRNA using Actinomycin D to block
transcription. Our results indicated that the rate of degradation of
RGC-32 mRNA was similar in the Akata and Mutu I latency I
lines compared to the Mutu III latency III cell-line, with the
message half-life estimated at approximately 1 hr in all cell-lines
(Figure 6). Since a potential translational block in latency I cells
does not lead to stabilization of RGC-32 mRNA, high RGC-32
mRNA levels in latency I cells appear to result from transcriptional
activation by RUNX1c and potentially other transcription factors
expressed in latency I cells (Figure 4).
To investigate the regulation of RGC-32 translation in latency I
and latency III cells, we next investigated whether RGC-32 was
associated with polyribsomes (polysomes) in both latency types.
Monosomal and polysomal-associated messages were separated
using sucrose gradient density centrifugation and the distribution
of RGC-32 and control messages in gradient fractions determined
using Q-PCR. Surprisingly, parallel analysis carried out in Akata
latency I cells and a latency III cell line, LCL#3 revealed that
RGC-32 mRNA was associated with polysomes in both cell lines,
indicative of association of multiple ribosomes with the RGC-32
message (Figure 7A). Both GAPDH and actin control messages
were associated with a high number of ribosomes or ‘heavy’
polysomes in both cell-lines, consistent with their constitutive high-
level expression. Similar results were obtained when parallel
analysis was carried out in latency I Mutu I cells and latency III
Mutu III cells (Figure 7B). Since RGC-32 mRNA is associated
with polysomes even when RGC-32 protein is absent in latency I
cells, these results indicate that RGC-32 translation is blocked at a
post-initiation stage. Post-initiation translational repression can
involve reduced translation elongation rates, ribosome drop-off or
co-translational protein degradation (involving proteasomal or
Figure 5. Proteasomal degradation or blocked mRNA export doesn’t prevent RGC-32 protein expression in latency I cells. (A) Mutu I,
Mutu III and IB4 cells were treated in parallel with 50 or 100 mM MG132 and harvested after 2 or 6 hrs for Western blot analysis. Blots were probed in
sections for RGC-32 and actin. IB4 blots were also probed for p53 as a control for MG132-mediated protein stabilization through proteasomal
inhibition. (B) Mutu I and III cells were fractionated into cytoplasmic (C) and nuclear (N) protein extracts and analysed by Western blotting for nuclear
(Spt16) and cytoplasmic (actin) marker proteins to confirm purity of the fractions. RGC-32 (C) and GAPDH (D) transcript levels were quantified by Q-
PCR in cytoplasmic (C) and nuclear (N) RNA extracts prepared in parallel to protein extracts.
doi:10.1371/journal.pone.0028638.g005
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post-initiation translational mechanism that blocks RGC-32
protein expression in latency I cells, a mechanism that is
presumably relieved in latency III cells.
Discussion
We have provided the first demonstration that protein
expression of the novel CDK1 activator, RGC-32, is upregulated
in cells immortalized by a human tumour virus, further supporting
a role for deregulated RGC-32 expression in tumour development.
Previous studies have described RGC-32 upregulation in ovarian,
colon, breast and prostate cancers indicating that deregulation of
the cell cycle by RGC-32 may play a key role in the aetiology of a
diverse range of tumours [31–33]. Since RGC-32 protein
expression is not detected in latency I Burkitt’s lymphoma cells
it is possible that the deregulated expression of c-Myc, resulting
from the Myc-Immunoglobulin translocation characteristic of BL,
alleviates the requirement for the proliferative advantage poten-
tially provided by RGC-32 protein expression in the EBV
transformed LCLs in which it is expressed. Further work is
needed to test the hypothesis that RGC-32 protein expression is
required for the proliferation of EBV transformed LCLs and RNA
interference experiments would be useful in this regard. It is
interesting that conversion of latency I BL cells to a latency III
EBV gene expression profile as observed in Mutu cells, or infection
of EBV negative BL cells is sufficient to ‘re-instate’ RGC-32
protein expression, indicating that latency III gene products play a
role in RGC-32 upregulation. Interestingly, other authors have
demonstrated that RGC-32 mRNA levels are positively regulated
by the EBV-encoded transcriptional regulators EBNA 3A and 3B
in LCLs and negatively regulated by EBNA 2 expression in an
EBV-negative B-cell-line [45–47], implicating interplay between
latency III gene products in fine-tuning RGC-32 mRNA
expression. These studies however did not address the effects of
these changes on RGC-32 protein expression and it is still unclear
what factors regulate RGC-32 protein expression in EBV-
transformed cells.
Since RGC-32 binds CDK1 in vitro and in vivo and increases
CDK1 activity in kinase assays [27–28], the upregulation of RGC-
32 in EBV-positive latency III cells led us to investigate whether
RGC-32 was a potential mediator of the deregulatory effects of
EBV on the G2/M checkpoint. Our data provide the first
evidence that overexpression of RGC-32 alone can disrupt the
G2/M checkpoint. In support of our observations, inducible
overexpression of testis-specific protein Y (TSPY) in HeLa cells has
been shown to upregulate RGC-32 and accelerate progression
through G2/M [48]. Interestingly, TSPY is located in the Y
chromosome gonadoblastoma oncogenic locus and is upregulated
in gonadoblastoma, testicular germ-cell tumours, prostate and
liver cancers and in melanoma [49–52].
Although we confirmed that RGC-32 activates CDK1/cyclin
B1 in vitro, the mechanism of CDK1 activation by RGC-32
remains to be fully elucidated. Although RGC-32 has no
homology to other human proteins, it may be functionally similar
to members of the Speedy/RINGO family of novel CDK
activators first described as inducers of G2/M progression in
Xenopus oocytes [53–54]. Significantly, overexpression of human
speedy 1 promotes G1/S transition and speedy/RINGO C
stimulates late S-phase progression and disrupts DNA damage-
induced G2 arrest [55–56]. RINGO family members have been
shown to bind and activate CDKs in the absence of cyclin,
through mechanisms that alleviate the requirement for activation
by CDK-activating kinase (CAK) and override the effects of
Figure 6. RGC-32 mRNA is not stabilized in latency I cell lines.
Cell-lines were treated with Actinomycin D and samples analysed at the
times indicated. RGC-32 mRNA levels were deteremined by Q-PCR and
normalized to those of the stable control message GAPDH. Results are
expressedrelativetotheleveldetectedattime0andshowthemean+/2
standard deviation of 4 independent experiments for Akata (A) or two
independent experiments for Mutu I (B) and Mutu III cells (C). Thehalf-life
values indicated were calculated using non-linear regression analysis.
doi:10.1371/journal.pone.0028638.g006
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PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e28638Figure 7. RGC-32 mRNA is associated with polysomes in latency I and latency III cells. Cytoplasmic extracts were sedimented on sucrose
density gradients and 0.5 ml or 1 ml fractions collected with continuous monitoring of absorbance at 254 nm (upper panels in A and B). 80S
monosome peaks are indicated by arrows. Transcript levels in each fraction were determined using Q-PCR and specific primers to RGC-32 (black bars),
GAPDH (open bars) and actin (grey bars). Transcript levels are expressed as a percentage of the total transcript levels detected across the gradient (nt
indicates fractions that were not tested). (A) Parallel analysis of Akata (latency I, no RGC-32 protein expression) and LCL#3 (latency III, RGC-32 protein
expressed) polysomes. (B) Parallel analysis of Mutu I (latency I, no RGC-32 protein expression) and Mutu III (latency III, RGC-32 protein expressed)
polysomes.
doi:10.1371/journal.pone.0028638.g007
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interesting to determine whether RGC-32-mediated activation
can be cyclin-independent, override inhibitory phosphorylation
and/or promote CDK1 activation through dephosphorylation.
Interestingly, Saigusa et al showed that RGC-32 interacts with the
centrosome-associated polo-like kinase 1 (Plk1) and is phosphor-
ylated by Plk1 in vitro, identifying another possible mediator of the
effects of RGC-32 on the cell cycle [30].
Surprisingly, Saigusa et al also identified RGC-32 as a potential
tumour suppressor gene deleted in malignant gliomas that could
suppress growth when re-introduced into glioma cell lines.
Overexpression of RGC-32 in HeLa cells also delayed progress
through G2/M [30]. Subsequent microarray analyses have
identified RGC-32 as a gene expressed at low level in multiple
myeloma plasma cells and drug resistant glioblastomas and RGC-
32 promoter methylation has been shown to correlate with RGC-
32 downregulation in non small cell lung cancers [35–37]. It is
therefore possible that the biological effects of RGC-32 may differ
between cell and tumour types and as a result RGC-32 may play
duel roles in oncogenesis and tumour suppression. Interestingly,
two regulators of RGC-32, TGF-b and RUNX1 also appear to
promote or repress tumourigenesis depending on the cell context,
developmental stage or tumour stage (for reviews see [58] and
[59]) and it is possible that some of the downstream effects of these
factors may be mediated through regulation of RGC-32
expression. Our results also highlight the fact that although a
number of microarray analyses have implicated RGC-32 down-
regulation in tumour development, gene expression analyses of this
type should be treated with caution until it is formally proven that
these RGC-32 mRNA expression changes result in a change in
protein expression.
The RUNX family of transcription factors (RUNX1, 2 and 3)
play key roles in many developmental processes including
hematopoiesis, osteogenesis and neurogenesis [60]. Rat RGC-32
was identified as a RUNX1 target and endogenous mouse RGC-
32 has been shown to be upregulated when either RUNX1, 2 or 3
are overexpressed in NIH 3T3 cells [42–44]. We now demonstrate
that RUNX1 activates RGC-32 transcription in human B-cell-
lines. RUNX1 and RUNX3 expression is inversely related in
human B-cell lines due to repression of RUNX1 transcription by
RUNX3 through direct interaction with sites in the RUNX1
promoter [41]. EBV infected latency III cells that express the EBV
transcriptional regulator EBNA 2 display high levels of RUNX3,
due to activation of RUNX3 transcription by EBNA2, and
corresponding low levels of RUNX1 [40]. By contrast, EBV
infected latency I cell-lines that do not express EBNA 2 have high
RUNX1 and low RUNX3 expression. Our results provide further
support for the differential roles of RUNX1 and RUNX3 in
human B-cell lines since RGC-32 mRNA levels mirror those of
RUNX1, but not RUNX3. Our results are in contrast to those in
NIH 3T3 cells where all three RUNX family members
upregulated mouse RGC-32 mRNA expression. It is clear that
the differential roles of RUNX1 and RUNX3 are cell-type and
context dependent since overexpression of RUNX1 or RUNX3 in
NIH3T3 cells provided a survival advantage under stress [44], but
RUNX 1 and not RUNX3 expression in EBV infected LCLs
blocks cell growth [61]. Since RUNX1c overexpression in
transient reporter assays resulted in only approximately 2-fold
increases in RGC-32 promoter activity, it is possible that other, as
yet unidentified transcription factors, may contribute to RGC-32
mRNA upregulation in latency I cells or that additional regulatory
elements not included in the reporter construct play an additional
role in transcriptional activation. Nonetheless, endogenous
overexpression of RUNX1c resulted in a 1.75-fold increase in
RGC-32 mRNA expression, supporting the role for RUNX1c in
regulating RGC-32 transcription.
We have identified a novel control point for regulating RGC-32
expression involving translational mechanisms. RGC-32 mRNA is
associated with polysomes even when not translated in latency I
cells, implicating a post-initiation mechanism for the control of
RGC-32 translation. Since miRNAs are known to regulate
translational elongation these results raise the possibility that
miRNAs may play a role in the regulation of RGC-32 expression.
Interestingly a number of cellular miRNAs have been previously
shown to be downregulated in EBV positive latency III cells
compared to EBV negative and latency I cells, a pattern expected
for a miRNA that blocks RGC-32 protein expression in latency I
but not latency III cells [62]. It will be interesting to test whether
the cellular miRNAs downregulated in latency III cells can repress
RGC-32 expression.
Additional clues to mechanisms that could contribute to the
inhibition of RGC-32 translation in latency I cell-lines come from
studies on the potential functional homologue of RGC-32, the
atypical CDK activator, RINGO. RINGO is expressed at the
mRNA level in G2 arrested Xenopus oocytes but RINGO protein is
undetectable due to translational repression by the RNA-binding
protein Pumilio-2 (PUM2) Pumilio-2 binds human PUM2 binding
element 1 (hPBE1, UNUUANNUGUA) or the human PUM2
binding element 2 (hPBE2, UAUANNUAGU) [63]. We have
identified a consensus hPBE2 element in the RGC-32 39UTR
implicating PUM2 as a potential regulator of RGC-32 translation.
Previous studies using RNA immunoprecipitation (RIP) tech-
niques to identify PUM2 or PUM2/DAZL co-associated mRNAs
have not detected PUM2 association with RGC-32 transcripts in
HeLa S3, HEK293 or testis mRNA samples [63-65]. Since our
studies point to B-cell specific mechanisms for the control of RGC-
32 translation, it will be interesting to determine whether PUM2 is
able to bind RGC-32 mRNA differentially in EBV-negative and
EBV-positive latency I and latency III B-cell-lines.
In summary, we have identified RGC-32 as a key cellular gene
that may play a role in promoting the survival and proliferation of
EBV-infected cells through deregulation of the G2/M cell-cycle
checkpoint. To further investigate the role of RGC-32 in EBV-
mediated tumourigenesis, it will be interesting to determine
whether RGC-32 expression levels are elevated in EBV-associated
post-transplant lymphomas that display the latency III pattern of
gene expression and whether RGC-32 protein expression in
required for the proliferation of EBV-infected latency III cells.
Our studies also reveal that novel post-initiation mechanisms
control RGC-32 protein expression in EBV infected B-cells. Since
these mechanisms may also control RGC-32 protein expression in
other cell-types and tumour tissues, our work highlights the need




To create pFLAG RGC-32, RGC-32 was amplified from BJAB
E3C-4 [66] cDNA, using primers designed to introduce 59 XbaI
and 39 BamHI sites (supplementary Table S1), and cloned into
pFLAG-CMV-2 (Sigma). pFRT RGC-32 was created by excising
the FLAG-RGC-32 sequence from pFLAG RGC-32 as a Sac1/
Sma1 fragment, removing the Sac1 overhang using mung bean
nuclease and ligating into EcoRV-digested pcDNA5/FRT
(Invitrogen). pRGC-32pluc was generated by amplifying a
1.25 kb fragment of the RGC-32 promoter (–1177 to +79 relative
to the predicted transcription start site) from genomic DNA, using
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(supplementary Table S1), and cloning into pGL2-Basic (Pro-
mega). pET-RGC-32 was generated by excising the RGC-32
sequence from pFLAG-RGC-32 as a SalI/BamHI fragment and
ligating into pET16b (Novagen) digested with XhoI/BamHI.
Cell lines and culture
The DG75 or BJAB FRT and FRT-RGC-32 cell lines were
generated using the Flp-In system (Invitrogen). EBV-negative
BJAB B-cell lymphoma cells [67] or DG75 Burkitt’s lymphoma
cells [68] were transfected with 10 mg linearised pFRT/lacZeo
(Invitrogen) via electroporation as described previously [69] to
create a stable Flp-In host cell line (BJAB/DG75 FRT). After 48 h
Zeocin was added to a final concentration of 400 mg/ml and cells
were diluted and aliquoted into 96-well plates to select single cell
clones. Genomic DNA was isolated from Zeocin-resistant clones
and Southern blot analysis (using a fragment of the lacZ gene as a
probe) was performed to determine the number of integrated FRT
sites. Cell lines containing single integrants were then screened for
beta-galactosidase activity and the line with the highest expression
level was stably transfected with 1.8 mg pOG44 (Invitrogen) and
0.2 mg pFRT RGC-32 plasmid using Amaxa nucleofection (kit T,
programme T-016). Cells were diluted in media containing
hygromycin B (200 mg/ml) 48 h after transfection and cultured
to obtain the isogenic hygromycin-resistant cell-lines BJAB FRT-
RGC-32 and DG75 FRT RGC-32. The BJAB and DG75 FRT
and FRT RGC-32 cell lines were routinely cultured in the
presence of 100 mg/ml Zeocin or 200 mg/ml hygromycin B
respectively.
The EBV-positive latency I and III Burkitt’s lymphoma cell
lines Mutu I (cl 179) and Mutu III (cl 48) [39], the IB4 LCL [70]
and most EBV negative and positive cell-lines not previously
described [69] were provided by Prof. Martin Rowe. The EBV-
negative Burkitt’s lymphoma cell lines BL2 and BL31 and their
EBV BAC infected derivatives were provided by Prof. Martin
Allday [15]. LCL#3 was provided by Dr Alison Sinclair [71]. All
cell-lines were passaged twice-weekly and cultured using previ-
ously described conditions.
Centrifugal elutriation and flow cytometry
Centrifugal elutriation (Beckman J6-MC centrifuge) was used to
separate the different cell-cycle phases as described previously [72]
. Mutu III cells were injected in a JE-5.0 rotor with a large
separation chamber at 1500 rpm and a flow rate of 30 ml per
minute controlled with a Cole-Palmer Masterflex pump. The rotor
speed was kept constant and fractions were collected at increasing
flow rates (35 ml per minute to 100 ml per minute). The DNA
content of the 40–80 ml fractions was determined by propidium




7 cells were gently resuspended in 1 ml of lysis buffer B
[73] (10 mM Tris pH 8.4, 140 mM NaCl, 1.5 mM MgCl2, 0.5%
NP40, 1 mM DTT and 200U/ml RNasin (Promega)) and the
cytoplasmic supernatant obtained by centrifugation at 2500 rpm
for 3 minutes at 4uC using a Sorvall Legend RT centrifuge. The
nuclear pellet was resuspended in 1 ml lysis buffer B containing 1/
10 volume (100 ml) of detergent (3.3% [wt/vol] sodium deoxy-
cholate and 6.6% [vol/vol] Tween 40) under slow vortexing and
the sample incubated on ice for 5 minutes. The nuclear material
was re-pelleted and then rinsed with 1 ml of lysis buffer B followed
by final pelleting of the nuclear fraction. The supernatant was
discarded. 1 ml of TriReagent (Sigma) was then added to both
nuclear and cytoplasmic fractions and RNA isolated. For SDS-
PAGE, 1 ml of 16 GSB [74] was added to the nuclear fraction
and the sample sonicated and 20 ml of the cytoplasmic fraction was
mixed with 5 ml5 6GSB.
RNA half-life determination
Cells were diluted to 4610
5/ ml 24 h prior to treatment with a
2 mM sub-toxic dose of actinomycin D (Sigma). Cells were
harvested after 0.5, 1, 2 and 4 h.
Proteasome inhibition
Cells were diluted to 3610
5/ ml 24 hrs before the experiment.
The proteasome inhibitor MG132 was added to a final
concentration of 50 or 100 mM and cells were harvested after 2
or 6 hours for SDS-PAGE analysis.
Transfection
For RUNX1 overexpression, 5610
6 IB4 cells in exponential
growth were transfected with 3 mg pCEP4 or pCEP4-RUNX1c
[61] (provided by Prof. Paul Farrell) using Amaxa kit T,
programme A-023 according to the manufacturer’s instructions.
24 hrs post-transfection, cells were selected in 200 mg/ml Hygro-
mycin B and harvested 6 days post-transfection.
For RGC-32 promoter reporter assays, the EBV-negative
Burkitt’s lymphoma cell-line DG75 was electroporated with
plasmid DNA at 230 V and 950 mF (BioRad Gene Pulser II)
and luciferase assays carried out as described previously [69]. Cells
were transfected with the RGC-32pLuc reporter and pRL-CMV
(Promega) as a transfection control, in the absence or presence of
pBK CMV RUNX1c (provided by Prof. Paul Farrell).
DNA damage and flow cytometry
Cells were diluted 24 hours prior to DNA damage and then
cultured in the presence of etoposide (Sigma) for 24 or 48 h. Cells
were fixed in 100% ethanol and 1610
6 cells were resuspended in
500 ml propidium iodide solution (0.1 mg / ml propidium iodide
(Sigma) in PBS containing 0.1% Triton X-100) followed by the
addition of 12 ml of 2 mg/ml RNase A (Invitrogen). Cells were
stained for 30 mins and cell cycle distribution was then analysed
using a FACsCaliber Flow Cytometer (BD Biosciences).
RGC-32 protein preparation
2 litres of E.coli BL21 plysS cells transformed with pET-RGC32
were induced to express His-RGC-32 by treatment with 1 mM
IPTG for 4 h at 37uC. Cell pellets were resuspended in 80 ml of
cold buffer A (40 mM PO4 buffer pH 7.5, 300 mM NaCl, 2 mM
benzamidine, 20 mM Imidazole, 3.5 mM b-mercaptoethanol,
protease inhibitor cocktail tablet (Roche)) and freeze-thawed 3
times. 10 mg/ml of DNase I was added and the lysate incubated
with rotation for 15 min at room temperature. Lysates were then
sonicated for 6610 s and the insoluble material pelleted by
centrifugation at 9.8 K rpm for 20 min in a Sorval SS-34 rotor at
4uC and then washed by resuspension in 20 ml buffer X (50 mM
HEPES (KOH) pH 7.5, 10 % glycerol, 2 mM benzamidine, 1 M
GuHCl). Brief sonication, centrifugation and washing steps were
repeated prior to denaturation of the protein pellet using 20 ml
buffer Y (50 mM HEPES (KOH) pH 7.5, 10 % glycerol, 2 mM
benzamidine, 6 M GuHCL). Samples were then re-sonicated
briefly and the remaining insoluble debris removed by centrifu-
gation. The supernatant was then added to 0.5 ml of NTi agarose
resin (Sigma) and mixed by rotation for 90 min at 4uC. Proteins
bound to the beads were then gradually refolded by washing twice
in 25 ml buffer A, twice in buffer B (40 mM PO4 buffer pH 7.5,
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b-mercaptoethanol, protease inhibitor cocktail tablet, 1% NP40),
twice in buffer C (40 mM PO4 buffer pH 7.5, 1 M NaCl, 2 mM
benzamidine, 20 mM Imidazole, 3.5 mM b-mercaptoethanol,
protease inhibitor cocktail tablet, 1% NP40) and twice in buffer
A. Protein was eluted three times using 1 ml elution buffer
(40 mM PO4 buffer pH 7.5, 300 mM NaCl, 100 mM EDTA) and
dialysed to remove EDTA.
Immunoblotting
SDS-PAGE and immunoblotting were carried out as described
previously [69,75]. The following antibodies were used for
immunoblotting: anti-actin 1/5000 (A-2066, Sigma), anti-CDK1
1/5000 (Cdc2 p34 sc-54), anti-cyclin B1 1/5000 (sc-245, Santa
Cruz Biotechnology), anti-RUNX1 1/40 (Ab-2, Calbiochem),
anti-Spt16 1/500, (sc-28734, Santa Cruz Biotechnology) and anti-
p53 1/1000 (DO.1, Santa Cruz Biotechnology). RGC-32 was
detected using polyclonal rabbit sera raised by Eurogentec against
recombinant His-RGC-32.
cDNA preparation
For analysis of cell-line panels, cells were diluted to 2610
5/ ml,
harvested after 3 days and total RNA extracted using TriReagent
(Sigma). RNA samples were purified using the RNeasy kit
(Qiagen) and cDNA synthesised using the ImProm II reverse
transcription system and random oligonucleotides (Promega). For
RNA half-life experiments, cDNA was prepared from 1610
5cells
using Power SYBR Green Cells-to-CT Kit (Applied Biosystems).
PCR
Quantitative PCR (Q-PCR) was performed in duplicate
generally using the standard curve absolute quantification method
on an Applied Biosystems 7500 real-time PCR machine as
described previously [75], and primers for RGC-32, RUNX1c,
GAPDH or actin (supplementary Table S1). For PCR across
exons 2-4 of RGC-32, cDNA was amplified using Taq polymerase
(New England Biolabs) according to the manufacturer’s recom-
mended conditions and 35 cycles of 94uC for 30 s, 55uC for 30 s
and 72uC for 1 min. For RNA half-life experiments, Q-PCR was
carried out using Power SYBR Green Cells-to-CT Kit (Applied
Biosystems) and RGC-32 or GAPDH specific primers followed by
analysis using the Relative Quantification (ddCt) method.
Kinase assays
Assays were carried out using the cdc2 kinase assay kit (Upstate)
and samples were analysed as described previously [75]. Assays
contained up to 5 mM His-RGC-32 protein and 2 units of
recombinant CDK1 (cdc2)/Cyclin B1 (NEB).
Northern blotting
Northern blotting was carried out essentially as described
previously [76] using 16 mg total cellular RNA isolated using
TriReagent (Sigma). RGC-32 transcripts were detected by
hybridization to a 360 bp XbaI/BamHI fragment from pFLAG-
RGC-32 containing the complete RGC-32 cDNA, labelled with
[a
32P-dCTP] using the ready to go DNA labelling bead kit
(Amersham). Blots were washed 3610 mins at room temperature
in 36 SSC, 0.1% SDS, 1610 mins in 0.5xSSC, 0.1% SDS and
2610 mins in 36SSC, 0.1% SDS at 65uC. Blots were stripped by
boiling in water and re-hybridized to a GAPDH probe generated
from a 1.3 kb EcoRI fragment from pBSK+GAPDH.
Polysome analysis
Sucrose gradient density centrifugation analysis was carried out
essentially as described previously but in the absence of heparin
[77]. Briefly, 3610
7 cells in exponential growth were resuspended
in fresh growth media at a concentration of 5610
5 cells/ml and
cultured for 1.5 hrs prior to analysis. Cycloheximide was then
added to a final concentration of 0.1 mg/ml for 5 min at 37uC
and the cells rapidly cooled in an ice bath. Following two washes in
PBS containing cycloheximide, cells were lysed in 500 ml polysome
extraction buffer and debris and nuclei removed prior to loading
on a 10–60% sucrose gradient as described [77]. Gradients were
sedimented at 38,000 rpm for 2 hrs in a SW40 Ti rotor at 4uC.
Gradient samples were collected as 0.5 ml or 1 ml fractions by
pumping 70% sucrose into the bottom of the gradient and
collecting from the top with continuous monitoring at 254 nm.
RNA was extracted from fractions by either the addition of 10 ml
10% SDS, 25 ml 0.5 M EDTA and 4 ml 20 mg/ml Proteinase K
for 1 hr at 37uC, followed by purification using the RNeasy kit
protocol (Qiagen) from step 4, or collecting fractions directly into
3 mls 8 M guanidine hydrochloride and processing as previously
described [77]. cDNA was then prepared and transcript levels
determined using Q-PCR analysis.
Supporting Information
Figure S1 Cell-cycle profiles of elutriated cell fractions.
Mutu III cells were separated into cell-cycle fractions by
centrifugal elutriation and a sample of each fraction analysed to
determine the cell-cycle phase using propidium staining of DNA
followed by flow cytometry. The cell-cycle phases attributed to the
majority of cells in each fraction based on DNA content are
indicated.
(PDF)
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